These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 10894820)

  • 1. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
    Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
    Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis.
    Huang Y; Ji ZS; Brecht WJ; Rall SC; Taylor JM; Mahley RW
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2952-9. PubMed ID: 10591675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
    de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
    J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice.
    Tsukamoto K; Maugeais C; Glick JM; Rader DJ
    J Lipid Res; 2000 Feb; 41(2):253-9. PubMed ID: 10681409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
    Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
    Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia.
    Huang Y; Liu XQ; Rall SC; Taylor JM; von Eckardstein A; Assmann G; Mahley RW
    J Biol Chem; 1998 Oct; 273(41):26388-93. PubMed ID: 9756870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase.
    de Man FH; de Beer F; van de Laarse A; Smelt AH; Leuven JA; Havekes LM
    Atherosclerosis; 1998 Feb; 136(2):255-62. PubMed ID: 9543096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice.
    Kypreos KE; Morani P; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2001 May; 40(20):6027-35. PubMed ID: 11352738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y; Liu XQ; Rall SC; Mahley RW
    J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production.
    Post SM; Groenendijk M; Solaas K; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):768-74. PubMed ID: 14962946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
    Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
    J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.
    Jong MC; Dahlmans VE; van Gorp PJ; Breuer ML; Mol MJ; van der Zee A; Frants RR; Hofker MH; Havekes LM
    Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):934-40. PubMed ID: 8696956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides.
    Hara M; Iso-O N; Satoh H; Noto H; Togo M; Ishibashi S; Kimura S; Kadowaki T; Hashimoto Y; Tsukamoto K
    Metabolism; 2006 Aug; 55(8):1129-34. PubMed ID: 16839851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
    Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
    J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.